Amorfix sets up vCJD blood screening assay in UK and begins to test blood donor samples

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today it has set up the EP-vCJD(TM) assay system in the Prion Laboratory at the British National Institute for Biological Standards and Control (NIBSC) and has begun to test fresh human blood samples as part of the ongoing assay validation process announced earlier this year.

"NIBSC and the UK National Blood Service have been exceedingly helpful in establishing the performance of the EP-vCJD(TM) assay on routine samples from blood donors," said Dr. George Adams, Chief Executive Officer of Amorfix. "We expect to finish this alpha-site testing program in a month and demonstrate the required specificity for the assay."

Experts in the UK believe people may be infected for decades before showing signs of vCJD. The number of people who contracted the disease by consuming BSE-positive products is unknown. To date, four people have been reported to have been infected through blood transfusion from donors who later developed symptoms and died from vCJD. Blood transfusion services in low-risk countries refuse to take blood from people who have lived in or visited high-risk countries, where BSE-positive cattle were prevalent, to slow the potential spread of the disease. A screening test for vCJD would allow more people to be blood donors and increase the safety of the blood transfusion services worldwide.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

%SEDAR: 00022789E

SOURCE: Amorfix Life Sciences Ltd.

Dr. George Adams, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899, This email address is being protected from spambots. You need JavaScript enabled to view it.; James Parsons, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899, This email address is being protected from spambots. You need JavaScript enabled to view it.